In vitro inhibition of head and neck cancer-cell growth by human recombinant interferon-alpha and 13-cis retinoic acid
Publication in refereed journal


Full Text

Times Cited
Web of Science11WOS source URL (as at 07/04/2021) Click here for the latest count

Other information
AbstractThree nasopharyngeal carcinoma (NPC) cell lines (CNE-1 CNE-2 and NPC/HK-1), two squamous cell carcinoma (SCC) cell lines (T2/CUHK and PWH-S1) and six head and neck cancer specimens (NPC [n = 4], SCC tongue [n = 1] and a thyroid cancer [n = 1]) were incubated with interferon (IFN)-alpha (5 x 10(4) iu/mL) and/or 13-cis retinoic acid (13RA: 10(-5) mol/L) for two days at 37 degreesC. In vitro chemosensitivity was measured using MTT assay. Mild growth inhibition of the five cell lines by IFN-alpha ranged from 7.1% to 51.8% (mean: 18.5%), whereas with 13RA it was zero to 19.7% (mean: 7%). Greater inhibition (14.8-51.0%, mean: 31.8%) was achieved when the two drugs were used in combination. Growth inhibition of the six surgical specimens ranged from 6.9% to 21% (mean: 13.6%) with IFN-alpha, zero to 10.3% (mean: 6.0%) with 13RA; and 6.6-26.5% (mean: 17.7%) when the two agents were combined. Four of the 11 samples showed synergistic antitumour effect when IFN-alpha and 13RA were combined, and six showed subadditive effect. The results show that IFN-alpha and 13RA have a mild in vitro antitumour effect on head and neck cancer cells, and the drug synergistic effect demonstrated in this study suggests that the two agents should be used in combination in clinical application.
All Author(s) ListLam PK, To EWH, Chan ESY, Liew CT, Lung IWH, King WK
Journal nameBritish Journal of Biomedical Science
Year2001
Month1
Day1
Volume Number58
Issue Number4
PublisherROYAL SOC MEDICINE PRESS LTD
Pages226 - 229
ISSN0967-4845
LanguagesEnglish-United Kingdom
Keywordshead and neck neoplasms; interferon-alpha; isotretinoin; retinoids
Web of Science Subject CategoriesMedical Laboratory Technology; MEDICAL LABORATORY TECHNOLOGY

Last updated on 2021-08-04 at 01:17